Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

04 janv. 2022 09h00 HE | Source: Genmab A/S

Genmab and Synaffix Enter into License Agreement for ADC Technology

Media Release Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologiesGenmab secures rights for conducting research on ADCs against multiple drug targets with options for...
03 janv. 2022 18h38 HE | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; January 4, 2022 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
03 janv. 2022 07h19 HE | Source: Genmab A/S

Genmab to Present at the 40th Annual J.P. Morgan Healthcare Conference

Media ReleaseCOPENHAGEN, Denmark; January 3, 2022Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 40th Annual J.P. Morgan...
14 déc. 2021 13h06 HE | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; December 14, 2021 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 15,541 shares as a consequence of the exercise of employee warrants. The...
13 déc. 2021 03h28 HE | Source: Genmab A/S

Genmab Announces that Janssen has Received Conditional European Marketing Authorization for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, after Failure of Platinum-base

Media ReleaseCopenhagen, Denmark, December 13, 2021 The European Commission has granted Janssen-Cilag International NV (Janssen) Conditional Marketing Authorization for RYBREVANT® (amivantamab) for...
22 nov. 2021 15h59 HE | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement Copenhagen, Denmark; November 22, 2021 – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses...
22 nov. 2021 15h53 HE | Source: Genmab A/S

Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Company Announcement Copenhagen, Denmark; November 22, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 7,959 restricted stock units to members of...
16 nov. 2021 13h11 HE | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; November 16, 2021 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 17,862 shares as a consequence of the exercise of employee warrants. The...
10 nov. 2021 11h00 HE | Source: Genmab A/S

Genmab Announces Financial Results for the First Nine Months of 2021

November 10, 2021; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2021 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Genmab and Seagen Inc....
04 nov. 2021 16h24 HE | Source: Genmab A/S

Genmab Improves its 2021 Financial Guidance

Company Announcement Genmab improves its 2021 financial guidance COPENHAGEN, Denmark; November 4, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that it is improving its 2021 financial guidance...

Page précédente

Page suivante